Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Sol-Gel Technologies (NASDAQ: SLGL), a dermatology-focused clinical-stage company, announced its participation in upcoming virtual investor conferences. CEO Dr. Alon Seri-Levy will speak at the Raymond James Institutional Investors Conference on March 1, 2021, at 8:20 AM ET, while CFO Gilad Mamlok will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A replay of the H.C. Wainwright presentation will be available on the company’s website for 30 days. The company continues to advance its pipeline of topical treatments for skin diseases.

NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Raymond James Institutional Investors Conference

Speakers:	Dr. Alon Seri-Levy, Chief Executive Officer
Date:	8:20 AM ET on March 1, 2021
Access:	Available to conference participants.

H.C. Wainwright Global Life Sciences Conference

Speakers:	Gilad Mamlok, Chief Financial Officer
Date:	March 9-10, 2021
Access:	Available on demand to conference participants.

A webcast replay of the presentation at H.C. Wainwright Life Sciences Conference will be available in the Investors/Events and Presentations section of the Company’s website at www.sol-gel.com for 30 days.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay^®, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Michael Levitan
Solebury Trout
+1-646-378-2920
mlevitan@soleburytrout.com

Source: Sol-Gel Technologies Ltd.

FAQ

When will Sol-Gel Technologies present at the Raymond James Institutional Investors Conference?

Sol-Gel Technologies will present on March 1, 2021, at 8:20 AM ET.

Who will represent Sol-Gel Technologies at the H.C. Wainwright Global Life Sciences Conference?

CFO Gilad Mamlok will represent Sol-Gel Technologies at the conference on March 9-10, 2021.

How can I access the replay of Sol-Gel's presentation at the H.C. Wainwright Conference?

A replay of the presentation will be available on Sol-Gel's website for 30 days in the Investors/Events section.

What is the focus of Sol-Gel Technologies?

Sol-Gel Technologies focuses on developing and commercializing topical drug products for skin diseases.

What products are in Sol-Gel Technologies' pipeline?

Their pipeline includes Twyneo for acne vulgaris, Epsolay for rosacea, and SGT-210 for palmoplantar keratoderma.